Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer

Pfizer heads into 2024 with a lower-than-expected sales forecast for its COVID-19 vaccine and treatment after weaker demand had already forced it to trim 2023 projections.

Source: washingtontimes.com

Please follow and like us: